

ALFONSO SAVIO

Elenco delle pubblicazioni

Nome : Alfonso
Cognome : Savio
Data di Nascita : 18/01/1969
Residenza : Via Sacramento a Foria 23, 80137 Napoli (NA)
Telefono : 081290397 – 3296937212
E-mail: info@adtec.it
Web: <http://www.adtec.it>
Cittadinanza : Italiana
Stato Civile : Sposato
Codice fiscale : SVALNS69A18F839U
Partita Iva. : 07016260635

Aggiornato a Giugno 2016

presenza nella sezione Acknowledgments per il supporto tecnico informatico

- a) C.Gridelli et al. *Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses*. Br J Cancer, 2000 Sep;83(6):707-14
- b) C.Gridelli, et al. *Carboplatin plus vinorelbine plus G-CSF support in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study*. Lung Cancer, 2002, 36: 327-32.
- c) C.Gridelli et al. *Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer*. Journal of the National Cancer Institute, 91: 66-72, 1999.
- d) G.Colucci et al *Randomized Phase III of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine as First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study* JCO, 2010, 48:1645-1651
- e) E. De Maio et al. *Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience*. Bio Med Central Cancer 2004, 5:30
- f) P.Maione, F.Perrone, C.Gallo, L.Manzione, F.Piantedosi, S.Barbera, S.Cigolari, F.Rosetti, E.Piazza, S.F.Robbati, O.Bertetto, S.Novello, M.R.Migliorino, A.Favaretto, M.Spatafora, F.Ferraù, L.Frontini, A.Bearz, L.Repetto, C.Gridelli. *Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study*. Journal of Clinical Oncology 2005, 23:6865-6872
- g) Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; on behalf of the GECO investigators. *Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study*. Lancet Oncol. 2007 Jun;8(6):500-12
- h) Gridelli C, Maione P, Illiano A, Piantedosi F, Favaretto A, A.Bearz, S.F.Robbati, V.Filippazzi, V.Lorusso, F.Carozza, R.V.Iaffaioli, L.Manzione, C.Gallo, A.Morabito, F. Perrone, on behalf of the MILES Investigators: *Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small cell lung cancer: the MILES-2P studies*. J Clin Oncol 25: 4663-4669, 2007
- i) E.Rossi, A.Morabito, E.De Maio, F.Di Rella, G.Esposito, A.Gravina, V.Labonia, G.Landi, F.Nuzzo, C.Pacilio, MC.Piccirillo, G.D'Aiuto, M.D'Aiuto, M.Rinaldo, G.Botti, C.Gallo, F.Perrone, A.de Matteis: *Endocrine effects of adjuvant letrozole plus triptorelin versus tamoxifen plus triptorelin in premenopausal patients with early breast cancer*. J Clin Oncol, in press 2007.

- j) C.Gridelli, E.De Maio, S.Barbera, M.Sannicolò, E.Piazza, FV.Piantedosi, L.Brancaccio, A.Morabito, P.Maione, F.Renda, G.Signoriello and F.Perrone on behalf of the MILES Investigators. *The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.* Lung Cancer, in press 2008.
- k) S.Pignata et al *Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial.* Oncology 2009;76:49–54
- l) V.Gebbia et al *Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial.* Lung Cancer 63 (2009) 251–258
- m) C.Pisano et al *A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.* Cancer Chemother Pharmacol (2009) 64:1021–1027
- n) C.Gridelli et al *Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.* Lung Cancer 67 (2010) 86–92
- o) C.Gridelli et al. *Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the MILES (Multicenter Italian Lung cancer in the Elderly Study) randomized trial.* Lung cancer, 2001, 31:277-284
- p) Morabito et al *Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study*

Presenza nella sezione autori

- a) G.De Feo et al *Time required to start multicentre clinical trials; a case study.* Annals of Oncology 2008 19, suppl 9
- b) G.De Feo et al *Impact of ministerial decree december 21st 2007 on time required to start multicentre clinical trials* 2009; 20 suppl 8
- c) G.De Feo et al *Time spent for activation of no-profit studies in Oncology in Italy july 2010; PlosOne 5,1*
- d) *Pignata et al Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial*
- e) *Pignata et al A RANDOMISED MULTICENTER PHASE II TRIAL TESTING THE*

*ADDITION OF PAZOPANIB TO WEEKLY PACLITAXEL IN PLATINUM RESISTANT
OR REFRACTORY ADVANCED OVARIAN CANCER (AOC). THE MITO 11 TRIAL*